2017 Vienna Best Oral Presentation – CET Award
18F-FDG PET/CT in pediatric lymphoma patients: the role of technologist
M.Ciaccio, C. Nava, D. Bonacina, M. Maurizio, A. Perri, A. Renaioli, S. Morzenti, L. Guerra, C. Crivellaro
2nd Nominee for Best Oral Presentation
Improving alignment between 18F-FDG PET and CT scans by controling breathing movements during the CT-scan
K. Lehnskov, C. P. Jønsson, L. B. Katz, D. A. Riisberg
3rd Nominee for Best Oral Presentation
A review of thyroid blockade strategies used in paediatric I123MIBG scintigraphy, and an evaluation of their relative effectiveness
B. Thurlow, T. Melhuish, P. Leanne, E. Morris, S. Johns, M. Guy, S. King, L. Biassoni
Best Poster Award
Residual Activity Correction Successfully Adjusts Myocardial Blood Flow Measurements in Time-efficient 13N-ammonia Myocardial Perfusion PET/CT
P. A. Doodeman, S. V. Lazarenko, F. M. van der Zant, M. Wondergem, R. J. J. Knol
2nd Nominee for Best Poster Presentation
Comparison of MPI SPECT/CT scans acquired with LEHR collimator and reduced time IQ SPECT system
S. Ferreira, P. Begley, M. Jessop, A. Aldous, N. Eftychiou, N. Singh, S. Dizdarevic, E. Sousa
3rd Nominee for Best Poster Presentation
A cost effective protocol for increasing patient throughout using a combination of half time imaging with 99mTc Tetrofosmin and Regadenoson in Stress Myocardial Perfusion Imaging
P. J. Turner, T. Watts, F. Whittingham
2016 Barcelona Best Oral Presentation – META Award
The diagnostic quality of 18-F-FDG PET images from the PET/MR in comparison with the PET/CT
E. Voets, M. G. W. Visser, F. M. Mottaghy, S. Vöö
2nd Nominee for Best Oral Presentation
First clinical experience with SUVmax cuantification by a dedecated breast PET compared to PET-CT.
3rd Nominee for Best Oral Presentation
A European phantom study to cross-calibrate myocardial 123I-mIBG scintigraphy
E. Poel, D. O. Verschure, K. Nakajima, K. Okuda, B. L. F. van Eck-Smit, G. A. Somsen, H. J. Verberne
Best Poster Award
Preoperative localisation of hyperfunctioning parathyroid glands; A preliminary comparison between99mTc-sestaMIBI / 123I scintigraphy and 18F-fluorocholine PET/CT
E. Jansen, M. Wondergem, F. M. Van der Zant, R. J. J. Knol
2nd Nominee for Best Poster Presentation
Calculating the Effective Dose from the CT Component of a SPECT/CT Study
A. M. Cheetham, G. Havariyoun, E. Kalogianni, D. Ruiz, L. Devlin, N. Gulliver, A. Eccles, N. Mulholland, G. Vivian
3rd Nominee for Best Poster Presentation
Upgrading Siemens software from Caredose mAs to both Caredose mAs and kV: Impact on patient radiation doses
B. Dall, C. Schulze, C. S. Knudsen, A. E. Ljunggren
2015  Hamburg Best Oral Presentation – META Award
Radiation Dose to the Eye Lens: Does Positioning Really Matter?
C. Baun, K. Falch, K. D. Nielsen, S. Shanmuganathan, O. Gerke, P. Hoeilund-Carlsen
2nd Nominee for Best Oral Presentation
Adaptation of 13N-NH3 and 18F-FDG Imaging Protocols for sarcoidosis for new scanner technology
C. Abreu, J. O’Doherty, S. Barrington, S. Pereira, L. Alves, J. John, P. Schleyer
3rd Nominee for Best Oral Presentation
Radionuclide therapy of metastatic melanoma with benzamide derivate I-131-BA100 after patient stratification with F-18-DOPA
F. O. Spohn, K. Kunze, F. Giesel, W. Mier, U. Haberkorn, C. Kratochwil
Best Poster Award
Evaluation of the quality of neuroimaging features as Alzheimer’s Disease biomarkers
F. Lucena, T. F. Vaz, J. Pé-Leve, A. S. Ribeiro, L. Lacerda, N. Silva, D. Nutt, J. McGonigle, H. A. Ferreira
2nd Nominee for Best Poster Presentation
Comparative retrospective study of peptide receptor radionuclide therapy (PRRT) with Y-90-DOTATOC and Y-90-DOTATATE in neuroendocrine tumours (NET)
M. Marx, H. Plagge, C. Winkler, Y. Zhao, U. Lützen, M. Zuhayra
3rd Nominee for Best Poster Presentation
Biodistribution Assessment of Sodium Pamidronate and Methylene Diphosphonate for Rats Bone Scintigraphy Images
T. S. C. Camozzato, A. Z. P. De Souza, M. Tizon, S. J. Garcia, V. F. Dutra1, T. G. Costa
2014  Gothenburg Best Oral Presentation – META Award
Role of Advanced Practitioner in the clinical setting of a multi-disciplinary clinic for alpha emitting 223Radium-dichloride therapy for bone metastases in castration-resistant prostate cancer
M. Jessop, A. Staker, K. Day, M. Aplin, N. Ryan, H. Cripps, A. Hosur, N. Singh, A. Robinson, S. Dizdarevic
2nd Nominee for Best Oral Presentation
Is it possible to use Teflon cannulae for Radionuclide Equilibrium Angiography?
M. Casanova Martins, C. Humphreys, A. Queiroz, C. Gascoigne, P. Ali
3rd Nominee for Best Oral Presentation
Quantitative assessment of 18-FDG PET/CT and dbPET: Relationship with Breast Cancer prognostic factors
R. Sanchez Jurado, M. Devis Saiz, A. Vicedo Gonzalez, J. Ferrer Rebolleda, J. Pamos Navas
Best Poster Award Research
Practice development in nuclear medicine technologists
P. Chilra, S. Gnesin,G.Allenbach, J. Prior, C. Marques, C. Masias-Valdés, F. Descombes, L. Vieira, J. A. P. Jorge
2nd Nominee for Best Poster Presentation
Comparison of Imaging Angle and Analysis Software on the Measurement of Left ventricular Ejection Fraction
W-C. Way, C.Huang, J. Lin, S.Wang
3rd Nominee for Best Poster Presentation
Interobserver and intraobserver variation of phase analysis results in ECG-gated myocardial perfusion SPECT related to repeated reconstructions
M. Hakala, T. Koivumaki, M. Hakulinen, M. Kokkonen, A. Leinonen, T. Laitinen
2013  Lyon Best Oral Presentation
How low can you go: Dose-reduction in Low-Dose CT-scans for attenuation correction in myocardial perfusion imaging
N. de Wit, B.J. Vermolen, P.J.G. Peeters, A.M. Scholtens, J.C.M. Buijs, H.W.A.M. de Jong
2nd Nominee for Best Oral Presentation
PET/CT imaging of head-neck patients: Comparison of a one-step protocol and a two-step protocol
C. S. Knudsen, A. Ljunggren, T. Beyer, F. Andersen, T. L. Klausen, K. Cappelen, A. K. Berthelsen, S. Holm, A. Loft
3rd Nominee for Best Oral Presentation
Simultaneous PET/MR in breast cancer-first results
C. Meisinger, I. Dregely, S. Schachoff, M. Schwaiger
Best Poster Award
Optimal number of iterations and attenuation correction method for the quantification of liver radioactivity on 99mTc-GSA SPECT/CT imaging
Y. Nakamura, S. Tomiguchi, N. Katsuda, M. Hashida
2nd Nominee for Best Poster Presentation
Evaluation of the basic characteristics of the cardiac focusing-collimators
A. Niwa, S. Abe, T. Odagawa, N. Fujita, H. Kono, T. Kumazawa, Y. Fujita, K. Kato
3rd Nominee for Best Poster Presentation
Causes and Actions in Relation to Defaulting Patients
T. Godskesen
Year City Winner
2017 Vienna Most Cited Paper – EJNMMI
PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions, Eur J Nucl Med Mol Imaging (2013) 40: 486. doi: 10.1007/s00259-012-2298-2, Author Block: Afshar-Oromieh, A., Malcher, A., Eder, M. et al.

Best Paper – EJNMMI
68Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients”, Eur J Nucl Med Mol Imaging (2016) 43: 34. doi:10.1007/s00259-015-3188-1Author Block: Sterzing, F., Kratochwil, C., Fiedler, H. et al.

Best Paper – EJNMMI
Extent of disease in recurrent prostate cancer determined by [68Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score, Eur J Nucl Med Mol Imaging (2016) 43: 397. doi:10.1007/s00259-015-3240-1, Author Block: Verburg, F.A., Pfister, D., Heidenreich, A. et al.

Best Paper – EJNMMI
Comparison of hybrid 68Ga-PSMA PET/MRI and 68Ga-PSMA PET/CT in the evaluation of lymph node and bone metastases of prostate cancer, Eur J Nucl Med Mol Imaging (2016) 43: 70. doi: 10.1007/s00259-015-3206-3, Author Block: Freitag, M.T., Radtke, J.P., Hadaschik, B.A. et al.

Best Paper – EJNMMI Physics
Physics of pure and non-pure positron emitters for PET: a review and a discussion, EJNMMI Phys (2016) 3:8. doi: 10.1186/s40658-016-0144-5, Author Block: Conti, M., Eriksson, L.

Best Paper – EJNMMI Research
The relationship between endogenous thymidine concentrations and [18F]FLT uptake in a range of preclinical tumour models, EJNMMI Research (2016) 6:63. doi:10.1186/s13550-016-0218-3, Author Block: Heinzmann, K. et al.

Best Paper – EJNMMI Radiopharmacy and Chemistry
New protein deposition tracers in the pipeline, EJNMMI Radiopharmacy and Chemistry (2016) 1:11. doi: 10.1186/s41181-016-0015-3, Author Block: Jovalekic, A. et al.

2016 Barcelona Most Cited Paper – EJNMMI
Prognostic value of metabolic tumor burden on F-18-FDG PET in nonsurgical patients with non-small cell lung cancerEur J Nucl Med Mol Imaging (2012) 39: 27. doi:10.1007/s00259-011-1934-6, Author Block: Liao, S., Penney, B.C., Wroblewski, K. et al.

Best Paper – EJNMMI
The diagnostic value of PET/CT imaging with the Ga-68-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate, Eur J Nucl Med Mol Imaging (2015) 42: 197. doi:10.1007/s00259-014-2949-6, Author Block: Afshar-Oromieh, A., Avtzi, E., Giesel, F.L. et al.

Best Paper – EJNMMI
Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors, Eur J Nucl Med Mol Imaging (2015) 42: 5. doi:10.1007/s00259-014-2893-5, Author Block: Bodei, L., Kidd, M., Paganelli, G. et al.

Best Paper – EJNMMI
F-18]THK-5117 PET for assessing neurofibrillary pathology in Alzheimer’s disease, Eur J Nucl Med Mol Imaging (2015) 42: 1052. doi:10.1007/s00259-015-3035-4, Author Block: Harada, R., Okamura, N., Furumoto, S. et al.

Most Downloaded Paper – EJNMMI Physics
Increased absorbed liver dose in Selective Internal Radiation Therapy (SIRT) correlates with increased sphere-cluster frequency, EJNMMI Phys (2015) 2: 10. doi:10.1186/s40658-015-0113-4, Author Block: Högberg, J., Rizell, M., Hultborn, R. et al.

Most Cited Paper – EJNMMI Research
Comparative gallium-68 labeling of TRAP-, NOTA-, and DOTA-peptides: practical consequences for the future of gallium-68-PET, EJNMMI Res (2012) 2: 28. doi:10.1186/2191-219X-2-28, Author Block: Notni, J., Pohle, K. & Wester, H.

2015 Hamburg EJNMMI Most Cited Paper
Automatic, three-segment, MR-based attenuation correction for whole-body PET/MR dataEur J Nucl Med Mol Imaging (2011) 38:138–152 DOI 10.1007/s00259-010-1603-1, Author Block: V. Schulz, I. Torres-Espallardo, S. Renisch, Z. Hu, N. Ojha et al.

EJNMMI Best Paper
Volume-based assessment by 18F-FDG PET/CT predicts survival in patients with stage III non-small-cell lung cancer, Eur J Nucl Med Mol Imaging (2014) 41:50–58 DOI 10.1007/s00259-013-2530-8, Author Block: J.Y. Choi, S. Hyup Hyun, H. Kyung Ahn, Hojoong Kim, Myung-Ju Ahn, Keunchil Park et al.

EJNMMI Best Paper
In vivo evaluation of a novel tau imaging tracer for Alzheimer’s disease, Eur J Nucl Med Mol Imaging (2014) 41:816–826 DOI 10.1007/s00259-013-2681-7, Author Block: V.L. Villemagne, S. Furumoto, M.T. Fodero-Tavoletti, R. S.Mulligan, John Hodges et al.

EJNMMI Best Paper
Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer, Eur J Nucl Med Mol Imaging (2014) 41:11–20 DOI 10.1007/s00259-013-2525-5, Author Block: A. Afshar-Oromieh, C. M. Zechmann, A. Malcher, Matthias Eder, Michael Eisenhut et al.

2014 Gothenburg EJNMMI Best Technical Paper
Comparison of lesion detection and quantitation of tracer uptake between PET from a simultaneously acquiring whole-body PET/MR hybrid scanner and PET from PET/CT, January 2013, Volume 40, Issue 1, pp 12-21, Dr. Carl von Gall

EJNMMI Best Basic Science Paper
Comparison of the binding characteristics of [18F]THK-523 and other amyloid imaging tracers to Alzheimer’s disease pathology, January 2013, Volume 40, Issue 1, pp 125-132, Dr. Nobuyuki Okamura

EJNMMI Best Clinical Paper
PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions, April 2013, Volume 40, Issue 4, pp 486-495, Dr. Afshar-Oromieh

EJNMMI Most Cited Paper
FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0January 2010, Volume 37, Issue 1, pp 181-200, Prof. Ronald Boellaard




2017 Vienna Dual-labeled PSMA-11 for PET/CT imaging and precise fluorescence guided intraoperative identification of prostate cancer
A. Baranski1, M. Schäfer1, U. Bauder-Wüst1, M. Roscher1, J. Schmidt1, E. Stenau1, T. Simpfendörfer2, L. Maier-Hein1, B. Hadaschik3, U. Haberkorn2, K. Kopka1, M. Eder4,1,5;
1German Cancer Research Center, Heidelberg, GERMANY, 2University Hospital, Heidelberg, GERMANY, 3University Hospital, Essen, GERMANY, 4University Hospital, Freiburg, GERMANY, 5German Cancer Consortium, Heidelberg, GERMANY.

First experience using LMI1195 in patients with the suspicion of pheochromocytoma or paraganglioma
C. Rischpler1, A. M. Schlitter1, M. Herz1, B. Yousefi1, A. von Werder1, R. Tauber1, T. Maurer1, K. Scheidhauer1, S. Robinson2, C. Orlandi2, S. G. Nekolla1, M. Schwaiger1;
1Technical University Munich, Munich, GERMANY, 2Lantheus Medical Imaging, N. Billerica, MA, UNITED STATES OF AMERICA.

TSPO-PET for high-grade glioma imaging using the novel ligand [18F]GE-180 – first in human results in the course of radiotherapy
M. Unterrainer1, D. Fleischmann1, S. Lindner1, A. Brunegraf1, F. Vettermann1, L. Vomacka1, M. Brendel1, R. Rupprecht2, C. Belka1, P. Bartenstein1, M. Niyazi1, N. Albert1;
1Ludwig-Maximilian-University Munich, München, GERMANY, 2University of Regensburg, München, GERMANY.

Monitoring tumor PD-L1 expression with microSPECT/CT during radiotherapy
S. Heskamp, J. D. M. Molkenboer-Kuenen, G. W. Sandker, P. J. Wierstra, J. Bussink, O. C. Boerman;
Radboud University Nijmegen Medical Centre, NIJMEGEN, NETHERLANDS.

Radiocobalt-labeled anti-HER1 affibody molecule DOTA-ZEGFR:2377 for imaging of low HER1 expression in prostate cancer pre-clinical model
B. Mitran1, J. Garousi1, M. Rosestedt1, E. Lindström1, K. G. Andersson2, S. Ståhl2, J. Löfblom2, V. Tolmachev1, A. Orlova1;
1Uppsala University, Uppsala, SWEDEN, 2KTH-Royal Institute of Technology, Stockholm, SWEDEN.

2016 Barcelona 68Ga-PSMA PET/CT for early restaging prostate cancer. Preliminary results of a prospective trial in patients with biochemical failure after radical therapy and PSA levels < 2 ng/mL
F. Ceci, P. Castellucci, T. Graziani, C. Fonti, F. Lodi, S. Boschi, S. Fanti; Service of Nuclear Medicine, S.Orsola-Malpighi Hospital, University of Bologna, Bologna, ITALY.

SPECT/CT imaging of the PD-1/PD-L1 immune checkpoint pathway in syngeneic murine tumor models
S. Heskamp, J. D. M. Molkenboer-Kuenen, R. H. A. M. van de Vondervoort, O. C. Boerman; Radboud University Nijmegen Medical Centre, NIJMEGEN, NETHERLANDS.

Feasibility of in vivo imaging of VEGFR2 expression using high affinity antagonistic biparatopic affibody construct ZVEGFR2-Bp2
B. Mitran1, R. Güler2, E. Lindström1, F. Fleetwood2, V. Tolmachev1, S. Ståhl2, A. Orlova1, J. Löfblom21Uppsala University, Uppsala, SWEDEN, 2KTH Royal Institute of Technology, Stockholm, SWEDEN.

Prognostic significance of molecular and imaging biomarkers in primary brain tumors
E. Lopci1, M. Riva1, L. Olivari2, F. Raneri2, A. Bizzi3, B. Fernandes1, P. Navarria1, F. Pessina1, M. Roncalli4, L. Bello1, A. Chiti41Humanitas Clinical and Research Hospital, Milano, ITALY, 2University of Milan, Milano, ITALY, 3Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, ITALY, 4Humanitas University, Milano, ITALY.

Value of F-DOPA PET in the long term follow up of radionecrotic brain metastases after radiosurgery: comparison with MRIF. Cicone1, L. Carideo1, C. Scaringi2, A. Romano3, A. Bozzao3, G. Minniti2, F. Scopinaro1; 1Unit of Nuclear Medicine, Sant’Andrea Hospital, “Sapienza” University of Rome, Rome, ITALY, 2Unit of Radiation Oncology, Sant’Andrea Hospital, “Sapienza” University of Rome, Rome, ITALY, 3Unit of Neuroradiology, Sant’Andrea Hospital, “Sapienza” University or Rome, Rome, ITALY.

2015  Hamburg A phage display derived stabilised bicyclic peptide targeting MMP-14 shows high imaging contrast in small animal PET imaging
A. M. Eder, S. Pavan, U. Bauder-Wüst, K. van Rietschoten, L. Baldassarre, U. Schierbaum, O. Seibert, K. Leotta, S. Campbell, H. Harrison, C. Stace, E. Walker, U. Haberkor, K. Kopka, D. P. Teufel; Radiopharmaceutical Chemistry, German Cancer Research Center, Heidelberg, Germany

Tc-99m-CXCL8 SPECT to image disease activity in inflammatory bowel disease
E. Aarntzen, D. De Jong, R. Hermsen, J. Drenth, O. Boerman, W. Oyen; Radboud UMC, Nijmegen, Netherlands

Blunted striatal dopamine release in cannabis dependence
E. van de Giessen, J. Weinstein, C. Cassidy, M. Haney, M. Slifstein, A. Abi-Dargham; Columbia University College of Physicians and Surgeons/New York State Psychiatric Institute, New York, United States of America.

Synergistically Enhanced Tumor Uptake via Dual-Targeting of CD105 and EGFR Using a “Click” Heterodimer
R. Hernandez, H. Luo, H. Hong, S. A. Graves, R. J. Nickles, W. Cai; University of Wisconsin-Madison, Madison, United States of America.

Metastatic control probability in patients with prostate cancer metastatic to bone treated 186Re-HEDP
A. M. Denis-Bacelar, A. Divoli, S. Chittenden, Y. Du, G. D. Flux; Institute of Cancer Research, London, United Kingdom

2014  Gothenburg Quantitative analyses at Baseline and Interim PET evaluation for response assessment and outcome definition in patients with Malignant Pleural Mesothelioma (MPM)
Egesta Lopci; Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS), HUMANITAS (Rozzano), Milano, Italy

A comparison of EGFR-targeted and non-targeted 177Lu-labeled gold nanoparticles (AuNPs) for localized radiation treatment of breast cancer xenografts in athymic mice
Simmyung Yook; University of Toronto, Leslie Dan Faculty of Pharmacy, Pharmaceutical Sciences, Toronto, Canada

Validation and applications for SNAP-tag imaging of bacterial infection.
Bethany Mills; University of Nottingham, Nottingham, United Kingdom

Non-FDG-avid areas inside a tumour mass in Paediatric Hodgkin Lymphoma (PHL) patients – A new risk factor?
Lars Kurch; University Hospital of Leipzig, Department of Nuclear Medicine, Leipzig, Germany

The QUEST Study: Correlating metabolic response with 90Y PET dosimetry for the treatment of metastatic liver cancer with radioembolisation
Kathy P. Willowson; University of Sydney, Sydney, Australia

2013  Lyon Development and pre-clinical evaluation of a new glucose-dependent insulinotropic polypeptide (GIP) based radioligand for PET imaging of a broad spectrum of neuroendocrine tumors
Eleni Gourni; University Hospital, Department of Nuclear Medicine, Freiburg, GERMANY

Synergistic anti-cancer response to chemotherapy and 177Lu-labelled APOMAB® radio immunotherapy in a preclinical model of lung cancer
Alexander Staudacher; Experimental Therapeutics Laboratory, Hanson Institute, Adelaide, AUSTRALIA

Tc99m labelled S-HYNIC Certolizumab Pegol for selecting patients for anti-TNFα treatment: a biodistribution and dosimetric study
Bieke Lambert; Department of Nuclear Medicine, Ghent University Hospital, BELGIUM

PET-guided radiotherapy planning in prostate cancer patients
Egesta Lopci; Humanitas Clinical and Research Center, Milan, ITALY

Evaluation of primary tumour and regional lymph node metastases with FDG PET/CT in breast cancer patients: prone versus supine position
Suzana Teixeira; Dutch Cancer Institute, Amsterdam, NETHERLANDS.




2017 Vienna PSMA-targeting alpha-Radiation therapy with 225Actinium-PSMA-617: Dosimetry, toxicity and duration of tumor-control
C. Kratochwil1, F. Bruchertseifer2, F. L. Giesel1, C. Apostolidis2, U. Haberkorn1, A. Morgenstern2;
1University Hospital Heidelberg, Heidelberg, GERMANY, 2EC-JRC, Directorate for Nuclear Safety and Security, Karlsruhe, GERMANY.
2016 Barcelona Secondary glioblastoma multiforme – local alpha emiters targeted therapy with 213Bi-DOTA-substance P
L. Królicki1, A. Morgenstern2, J. Kunikowska1, H. Koziara3, B. Królicki3, M. Jakuciński4, D. Pawlak5, C. Apostolidis2, F. Bruchertseifer2;
1 Department of Nuclear Medicine, Medical University of Warsaw, Warsaw, Poland, 2 European Commission, Joint Research Centre, Institute for Transuranium Elements, Karlsruhe, Germany, 3 Department of Neurosurgery, Institute of Psychiatry and Neurology, Warsaw, Poland, 4 Department of Nuclear Medicine, Brodnowski Hospital, Warsaw, Poland, 5 Radioisotope Centre POLATOM, National Centre for Nuclear Research, Otwock, Poland
2015  Hamburg Feasibility of Affibody molecule-based PNA-mediated pretargeting
A. Honarvar et al., Uppsala University, Uppsala, SWEDEN
2014  Gothenburg Visualising Parasympathetic Denervation in Parkinson’s Disease – [11C]donepezil PET for Imaging Acetylcholinesterase Density in Peripheral Organs (Part I)
P. Borghammer et al. Aarhus University Hospital, Aarhus, Denmark
2013  Lyon A new route toward enhancing the uptake of [111In/177Lu-DOTA,Leu15]MG11 in CCK2R-positive xenografts in mice
A. Kaloudi1, B. A. Nock1, E. Lymperis1, P. J. Marsouvanidis1,2, E. P. Krenning2, M. de Jong2,3, T. Maina-Nock1;
1Molecular Radiopharmacy, INRASTES, NCSR Demokritos, Athens, GREECE, 2Department of Nuclear Medicine, Erasmus MC, Rotterdam, NETHERLANDS, 3Department of Radiology, Erasmus MC, Radiology, NETHERLANDS.
2012  Milan Detection of prostate cancer using 68Ga-labelled bombesin analogue BAY 86-7548 in patients undergoing radical prostatectomy
H. Minn2,5, E. Kähkönen1, I. Jambor2,3, J. Kemppainen2,4, K. Lehtiö5, J. Silén2, A. Kuisma5, P. Luoto2, T. Tolvanen2, K. Alanen6, T. Grönroos2, M. Kallajoki6, A. Roivainen2, N. Schäfer7, R. Schibli8, M. Dragic8, A. Johayem9, R. Valencia10, S. Borkowski10;
1Department of Surgery, Division of Urology, Turku University Hospital, Turku, Finland, 2Turku PET Centre, University of Turku, Turku, Finland, 3Department of Diagnostic Radiology, University of Turku, Turku, Finland, 4Department of Clinical Physiology and Nuclear Medicine, Turku University Hospital, Turku, Finland, 5Department of Oncology and Radiotherapy, Turku University Hospital, Turku, Finland, 6Department of Pathology, Turku University Hospital, Turku, Finland , 7Department of Medical Oncology and Nuclear Medicine, University Hospital of Zurich, Zurich, Switzerland, 8Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland , 9Department of Nuclear Medicine, University Hospital of Zurich, Zurich, Switzerland, 10Bayer Pharma AG, Berlin, Germany
2011  Birmingham Longitudinal imaging of transplanted islets in a rat model with SPECT
K. Andralojc, M. Brom, L. Claessens-Joosten, D. Bos, W. Oyen, O. Boerman, M. Gotthardt;
Radboud University & Medical Center Nijmegen, NETHERLANDS
2010  Vienna VEGF Immuno-PET with 89Zr-ranibizumab during sunitinib treatment
M. N. Lub-de Hooge, W. B. Nagengast, J. A. Gietema, S. F. Oosting, M. A. de Korte, F. Warnders, H. Timmer-Boscha, G. A. Hospers, J. R. de Jong, W. F. den Dunnen, H. Hollema, R. A. J. O. Dierckx, E. G. E. de Vries;
University Medical Center Groningen, Groningen, NETHERLANDS
2009  Barcelona Development of an improved amyloid probe, [11C]AZD2184. From pre-clinical to clinical in vivo PET measurements in AD patients
J. Andersson1, K. Varnäs1, Z. Cselényi2, B. Gulyás1, B. Swahn3, S. Finnema1, S. Nyberg2, L. Farde2, C. Halldin1;
1Karolinska Institutet, Stockholm, SWEDEN, 2AstraZeneca Pharmaceuticals Neuroscience Clinical, Södertälje, SWEDEN, 3Department of Medicinal Chemistry AstraZeneca R&D, Södertälje, SWEDEN
2008  Munich Intravesical α-radioimmunotherapy with Bi-213-anti-EGFR-MAb defeats human bladder carcinoma in xenografted nude mice
B. Pfost1, C. Seidl1, M. Autenrieth2, D. Saur3, F. Bruchertseifer4, A. Morgenstern4, M. Schwaiger1, R. Senekowitsch-Schmidtke1
1Department of Nuclear Medicine, Technische Universität München, München, GERMANY, 2Department of Urology, Technische Universität München, München, GERMANY, 3II. Medizinische Klinik und Poliklinik, Technische Universität München, München, GERMANY, 4European Commission, JRC, Institute for Transuranium Elements, Karlsruhe, GERMANY
2007  Copenhagen Converging evidence for specific neurotoxic effects of ecstasy on the thalamus: [123I]β-CIT SPECT and advanced MRI studies
M. de Win et al.University Hospital Amsterdam, Amsterdam, The Netherlands
2006  Athens Early predictive value of positron emission tomography with [18F]-fluorodeoxyglucose for the pathologic complete response of primary tumor in breast cancer patients treated by neoadjuvant chemotherapy.
A. Berriolo-Riedinger et al Centre G.F. Leclerc, Dijon, France
2005  Istanbul A comparison of amphetamine induced changes in agonist and antagonist radioligand binding potential on the dopamine D2 receptor in primate brain
N. Seneca, S. Finnema, M. Ichise, B. Gulyas, H. Wikstrom, R. Innis, L. Farde, C. Halldin (Stockholm, Bethesda, Groningen)
2004  Helsinki 99mTC Interleukin-2 (99m TC-IL2) Scintigraphy for Imaging Vulnerable Atherosclerotic Plaques
A. Signore, A. Annovazzi, E. Bonnano, M. Arca, C. D’Alessandria, A. Marcoccia, L. Spagnoli, F. Violi, F. Scopinaro, G. De Toma (Rome)
2003  Amsterdam Radioimmunotherapy with Lutetium-177-DOTA-Rituximab: a Phase I/II-Study in Patients with Follicular and Mantle Cell Lymphoma. An interim Analysis
F. Forrer, A. Lohri, H.Uusijärvi, G. Moldenhauer, J. Chen, R. Herrmann, E. Nitzsche, H. Mäcke, J.Müller-Brand (Basel, Liestal, Gothenburg)
2002  Vienna Combined [11C]Raclopride-PET and voxel based morphometry analysis in early Huntington´s disease: separating between functional and morphological alterations
F.D. Juengling, J. Karitzky, C. Solbach, J. Kassubek, C. Saft, B. Heinen, S.N. Reske, T. Kioschies, K. Henkel (Ulm)
2001 Naples [11C]MADAM – a highly suitable radioligand for examination of the serotonin transporter with PET
C. Halldin, D. Guilloteau, J. Tarkiainen, J. Sóvágó, B. Gulyás, J. Sandell, P. Emond, J. Vercouillie, S. Chalon, J. Hiltunen, L. Farde
2000 Paris Partial reversibility and gender differences in the toxic effects of MDMA (‘ecstasy’) on brain serotonin neurons
L. Renemann, J. Booij , K. De Bruin , F.A. De Wolff , W. van den Brink, G.J. Den Heeten (Amsterdam)
1999 Barcelona Low- versus high-dose radioimmunotherapy with humanized anti-CD20 antibodies in a broad spectrum of B-cell associated malignancies
T.M. Behr , B. Wörmann, M. Gramatzki, M. Béhé, F. Griesinger, W. Hiddemann, D.M. Goldenberg, W. Becker (Göttingen)
1998 Berlin Lymphoscintigraphy and radioguided biopsy of the sentinel axillary node in breast cancer
G. Paganelli, C. DeCicco , M. Cremonesi, A. Luini, M. Bartolomei, C. Grana , G. Prosco , V. Galimberti, P. Calza, G. Viale, U. Veronesi (Milan)
1997 Glasgow Coronary revascularization improves survival and left ventricular function in patients with chronic coronary artery disease and dysfunctional but viable myocardium at thallium-201 imaging
A. Cuoculo, E. Nicolai, M. Petretta, L. Pace, S. Cardei, A. Varrone, B. Trimarco, M. Salvatore (Naples)
1996 Copenhagen Relationship between clinical features of Parkinson’s disease and presynaptic dopamine transporter function assessed with I-123 IPT and SPECT
K. Tatsch, P.D. Mozley, J. Schwarz, R. Linke, O. Pogarell, R.S. Fieber, K. Hahn, H.F. Kung (Munich)
1995 Brussels Imaging of 5-HT1a receptors in human brain using (C-11)Way-100635 and PET
V. Pike, J. McCarron, S. Hume, S. Ashworth, J. Opcka-Juffry, A. Lammerstma, K. Poole, A. Malizia, C. Bench, P. Grasby, I. Cliffe, A. Fletcher (London)
1994 Düsseldorf Recombinant human interleukin-1: a potential agent to image infectious foci
J. van der Laken, I.C. Boerman, W.J.G. Oyen, M.T.P. van de Ven, J. Makarewicz, R.A.M.J. Claessens, J.W.M. van der Meer, F.H.M. Corstens (Nijmegen
1993 Lausanne Comparison of 123-I-alpha-methyl tyrosine SPECT and 11C-L-methionine PET in patients with brain tumors: initial results
K.J. Langen, B. Hamacher, K. Ziemons, T. Kuwert, U. Braun, H. Herzog, J.C.W. Kiwit, B. Nebeling, G. Stöcklin, H.W. Müller- Gärtner (Düsseldorf, Jülich)
1992 Lisbon Preparation of (11C)ß-CIT, a new ligand for imaging cocaine binding sites in vivo by PET
C. Halldin, L. Farde, L. Müller, P. Karlsson, J.L. Neumeyer, Y. Gao, R. Milius, H. Hall, C.G. Swahn (Stockholm, Natick)
1991 Vienna PET studies of human cerebral malignancy with (2-11C) thymidine (TRD) and (18F)FDG
T. van der Borght, S. Pauwels, L. Lambotte, L.D. Labor, S. De Maeght, G. Stroobandt, C. Laterre (Brussels)
1990 Amsterdam Ventilation and perfusion in a single image
J.J.P. de Lima, M.F.R. Botelho, A.M.S. Pereira, J.A.S. Rafael, M.A.T. Marques, A.J. Pinto, F. Godinho, M.C. Pereira, M.F. Baganha (Aveiro, Coimbra, Lisbon)
Back to top
This website uses cookies. Learn more